Home/News Feed/ACADIA Pharmaceuticals beats Q2 earnings and revenue estimates, raising 2026 revenue forecast and price target.

ACAD

$20.20

-$0.24 -1.17%

ACADIA Pharmaceuticals beats Q2 earnings and revenue estimates, raising 2026 revenue forecast and price target.

Company Fundamentals

10 Aug 2026

Andrew Wynn

View Source

Bullish

ACADIA Pharmaceuticals beats Q2 earnings and revenue estimates, raising 2026 revenue forecast and price target.

ACADIA Pharmaceuticals reported strong Q2 2026 results, with earnings of $0.18 per share beating estimates by 200% and revenues of $307.96 million surpassing forecasts by nearly 5%. Driven by increased sales of key drugs Daybue and Nuplazid, the company raised its 2026 revenue forecast to $1.24-$1.30 billion. Citigroup reaffirmed a "Buy" rating and raised the price target from $35 to $39, reflecting confidence in ACADIA's growth prospects and solid financial performance.

More News (ACAD)

Law firm probes ACADIA Pharmaceuticals over possible securities fraud after trial results drop stock.

Pomerantz LLP is investigating ACADIA Pharmaceuticals and some of its executives for potential securities fraud following the company's announcement of disappointing Phase 2 trial results for its Alzheimer's drug remlifanserin. The trial narrowly mis...

Market News

Bearish

1 day ago

ACADIA Pharmaceuticals beats Q2 earnings and revenue estimates, raising 2026 revenue forecast and price target.

More News (ACAD)

Law firm probes ACADIA Pharmaceuticals over possible securities fraud after trial results drop stock.

Invest & Trade with#1 Award-Winning Investment Super App

Invest & Trade with
#1 Award-Winning Investment Super App